Correction of Psoriatic T Cell Signatures by Deucravacitinib
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis
before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker,
deucravacitinib.